A microneedle less than a millimeter in length is used to inject a natural and...
A microneedle less than a millimeter in length is used to inject a natural and biodegradable polymer material into a structure in the eye. The material forms a hydrogel that holds open a pathway to release pressure from the eye.
Source: Gary Meek, Georgia Tech

Hydrogel: an option for glaucoma treatment?

Researchers have developed a potential new treatment for the eye disease glaucoma that could replace daily eyedrops and surgery with a twice-a-year injection to control the buildup of pressure in the eye. The researchers envision the injection being done as an office procedure that could be part of regular patient visits.

The possible treatment, which could become the first non-drug, non-surgical, long-acting therapy for glaucoma, uses the injection of a natural and biodegradable material to create a viscous hydrogel — a water-absorbing crosslinked polymer structure — that opens an alternate pathway for excess fluid to leave the eye.

“The holy grail for glaucoma is an efficient way to lower the pressure that doesn’t rely on the patient putting drops in their eyes every day, doesn’t require a complicated surgery, has minimal side effects, and has a good safety profile,” said Ross Ethier, professor and Georgia Research Alliance Lawrence L. Gellerstedt Jr. Eminent Scholar in Bioengineering in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University. “I am excited about this technique, which could be a game-changer for the treatment of glaucoma.”

As many as 75 million people worldwide have glaucoma, which is the leading cause of irreversible blindness. Glaucoma damage is caused by excess pressure in the eye that injures the optic nerve. Current treatments attempt to reduce this intraocular pressure through the daily application of eyedrops, or through surgery or implantation of medical devices, but these treatments are often unsuccessful.

To provide an alternative, Ethier teamed up with Mark Prausnitz, professor and J. Erskine Love Jr. Chair in the School of Chemical and Biomolecular Engineering at Georgia Tech, to use a tiny hollow needle to inject a polymer preparation into a structure just below the surface of the eye called the suprachoroidal space (SCS). Inside the eye, the material chemically crosslinks to form the hydrogel, which holds open a channel in the SCS that allows aqueous humor from within the eye to drain out of the eye through the alternative pathway.

There are normally two pathways for the aqueous humor fluid to leave the eye. The dominant path is through a structure known as the trabecular meshwork, which is located at the front of the eye. The lesser pathway is through the SCS, which normally has only a very small gap. In glaucoma, the dominant pathway is blocked, so to lessen pressure, treatments are created to open the lesser pathway enough to let the aqueous humor flow out.

In this research, the hydrogel props open the SCS path. A hollow microneedle less than a millimeter long is used to inject a droplet (about 50 microliters) of the hydrogel-precursor material. That gel structure can keep the SCS pathway open for a period of months. “We inject a viscous material and keep it at the site of the injection at the interface between the back of the eye and the front of the eye where the suprachoroidal space begins,” Prausnitz said. “By opening up that space, we tap a pathway that would not otherwise be utilized efficiently to remove liquid from the eye.”

The injection would take just a few minutes, and would involve a doctor making a small injection just below the surface of the eye in combination with numbing and cleaning the injection site. In the study, the researchers, including veterinary ophthalmologist and first author J. Jeremy Chae, did not observe significant inflammation resulting from the procedure.

The treatment could replace daily eye drops and surgery with a twice-a-year...
The treatment could replace daily eye drops and surgery with a twice-a-year injection to control the buildup of pressure in the eye.
Source: Rob Felt, Georgia Tech

The pressure reduction was sustained for four months. The researchers are now working to extend that time by modifying the polymer material — hyaluronic acid — with a goal of providing treatment benefits for at least six months. That would coincide with the office visit schedule of many patients. “If we can get to a twice-a-year treatment, we would not disrupt the current clinical process,” Prausnitz said. “We believe the injection could be done as an office procedure during routine exams that the patients are already getting. Patients may not need to do anything to treat their glaucoma until their next office visit.”

Beyond extending the time between treatments, the researchers will need to demonstrate that the injection can be repeated without harming the eye. The procedure will also have to be tested in other animals before moving into human trials. “The idea of having a ‘one-and-done’ treatment that lasts for six months would be particularly helpful for those whose access to healthcare is non-optimal,” Ethier said. “Having a long-acting therapy would have an additional advantage during times of pandemic or other disruption when access to healthcare is more difficult.”

The research was published in Advanced Science.

Subscribe to our newsletter

Related articles

Hydrogel contact lenses for therapeutic use

Hydrogel contact lenses for therapeutic use

Researchers at the Terasaki Institute have developed prototypes of contact lenses that can assist with tear sampling for diagnostic purposes.

Cryomicroneedles for intradermal therapeutic cell delivery

Cryomicroneedles for intradermal therapeutic cell delivery

Scientists have developed a new generation of microneedles technology which allows the intradermal delivery of living cells in a minimally invasive manner.

Hydrogel can repair tears in human tissue

Hydrogel can repair tears in human tissue

Scientists have developed an injectable gel that can attach to various kinds of soft internal tissues and repair tears resulting from an accident or trauma.

Hydrogel injection may repair heart muscle damagage

Hydrogel injection may repair heart muscle damagage

Researchers have developed an injectable hydrogel that could help repair and prevent further damage to the heart muscle after a heart attack.

Microneedle patch delivers drugs and procures testing samples

Microneedle patch delivers drugs and procures testing samples

Researchers have developed a biobattery-powered device capable of both delivering large molecule pharmaceuticals across the skin barrier and extracting interstitial fluid for diagnostic purposes.

Smart contact lens to combat eye deficiencies

Smart contact lens to combat eye deficiencies

Researchers have developed an artificial iris integrated inside a contact lens that can automatically set the proper pupil size to achieve optimal focus and depth of field.

3D printed hydrogels to be used in cancer immunotherapy

3D printed hydrogels to be used in cancer immunotherapy

The new 3D hydrogels provide high rates of cell proliferation, as they mimic lymph nodes, where T-cells reproduce in vivo.

A new way to deliver drugs through the skin

A new way to deliver drugs through the skin

Scientists have showed that applying "temporal pressure" to the skin of mice can create a new way to deliver drugs.

Melanoma: patch may be a treatment option

Melanoma: patch may be a treatment option

Scientists at Purdue University have developed a skin patch that can deliver chemotherapy into melanoma tumors in an effective and painless way.

Popular articles

Subscribe to Newsletter